A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19
…, SM Lofgren, EC Okafor, CP Skipper… - New England journal …, 2020 - Mass Medical Soc
Background Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the …
respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the …
Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial
CP Skipper, KA Pastick, NW Engen… - Annals of internal …, 2020 - acpjournals.org
Background: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).
Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in …
Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in …
Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19)
…, F Wang, SM Lofgren, CP Skipper… - Open forum …, 2020 - academic.oup.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral
infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and …
infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and …
Hydroxychloroquine as pre-exposure prophylaxis for coronavirus disease 2019 (COVID-19) in healthcare workers: a randomized trial
…, AS Bangdiwala, MR Nicol, CP Skipper… - Clinical Infectious …, 2021 - academic.oup.com
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly
emerging virus causing the ongoing coronavirus disease 2019 (COVID-19) pandemic with no …
emerging virus causing the ongoing coronavirus disease 2019 (COVID-19) pandemic with no …
Symptoms of COVID-19 outpatients in the United States
MF Pullen, CP Skipper, KH Hullsiek… - Open forum …, 2020 - academic.oup.com
Background Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel
pathogen causing the current worldwide coronavirus disease 2019 (COVID-19) pandemic. Due …
pathogen causing the current worldwide coronavirus disease 2019 (COVID-19) pandemic. Due …
Safety of hydroxychloroquine among outpatient clinical trial participants for COVID-19
…, KA Pastick, EC Okafor, CP Skipper… - Open forum …, 2020 - academic.oup.com
Background Use of hydroxychloroquine in hospitalized patients with coronavirus disease
2019 (COVID-19), especially in combination with azithromycin, has raised safety concerns. …
2019 (COVID-19), especially in combination with azithromycin, has raised safety concerns. …
Oral lipid nanocrystal amphotericin B for cryptococcal meningitis: a randomized clinical trial
…, E Kigozi, C Muzoora, J Ellis, CP Skipper… - Clinical Infectious …, 2023 - academic.oup.com
Background Amphotericin B is the gold standard treatment for severe mycoses. A new orally
delivered, less-toxic formulation of amphotericin has been developed. Methods In our …
delivered, less-toxic formulation of amphotericin has been developed. Methods In our …
Phase I EnACT trial of the safety and tolerability of a novel oral formulation of amphotericin B
CP Skipper, M Atukunda, A Stadelman… - Antimicrobial agents …, 2020 - Am Soc Microbiol
Amphotericin B deoxycholate (AMB) has substantial toxicities. A novel encochleated
amphotericin B deoxycholate (cAMB) formulation has oral bioavailability, efficacy in an animal …
amphotericin B deoxycholate (cAMB) formulation has oral bioavailability, efficacy in an animal …
Recurrence of symptoms following cryptococcal meningitis: characterizing a diagnostic conundrum with multiple etiologies
NC Bahr, CP Skipper, K Huppler-Hullsiek… - Clinical Infectious …, 2023 - academic.oup.com
Background Cryptococcal meningitis is a common cause of AIDS-related mortality. Although
symptom recurrence after initial treatment is common, the etiology is often difficult to …
symptom recurrence after initial treatment is common, the etiology is often difficult to …
Outpatient cryptococcal antigen screening is associated with favorable baseline characteristics and improved survival in persons with cryptococcal meningitis in …
…, DB Meya, DR Boulware, CP Skipper - Clinical Infectious …, 2023 - academic.oup.com
Background It is unknown whether persons with symptomatic cryptococcal meningitis
detected during routine blood cryptococcal antigen (CrAg) screening have better survival than …
detected during routine blood cryptococcal antigen (CrAg) screening have better survival than …
